RPL17 and neoplasm: Similarly, for patients with metastatic non-small cell lung cancer (NSCLC) that are being considered for treatment with the anti-PD- 1 cemiplimab, their tumor must have a tumor proportion score ([TPS] (percentage of viable tumor cells showing partial or complete membrane staining at any intensity) of at least 50% [43].